DreamCIS, Inc. (KOSDAQ:223250)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,150.00
-180.00 (-3.38%)
At close: Mar 12, 2026
Market Cap126.57B +69.1%
Revenue (ttm)62.06B +9.1%
Net Income18.58B +297.5%
EPS780.86 +302.3%
Shares Out24.58M
PE Ratio6.60
Forward PE12.91
Dividendn/a
Ex-Dividend Daten/a
Volume82,942
Average Volume279,559
Open5,280.00
Previous Close5,330.00
Day's Range5,080.00 - 5,330.00
52-Week Range2,435.00 - 8,070.00
Beta0.32
RSI41.18
Earnings DateMar 20, 2026

About DreamCIS

DreamCIS, Inc. operates as a clinical research organization in South Korea. It offers clinical development services; biostatics, data and project management, pharmacovigilance, medical writing, site start up, clinical monitoring, Dreamtrial, IWRS, and quality assurance services; medical device development services; and regulatory consulting services. The company was founded in 2000 and is headquartered in Seoul, South Korea. DreamCIS, Inc. operates as a subsidiary of Hangzhou Tigermed Consulting Co., Ltd. [Read more]

Industry Commercial Physical and Biological Research
Founded 2000
Employees 390
Stock Exchange KOSDAQ
Ticker Symbol 223250
Full Company Profile

Financial Performance

In 2024, DreamCIS's revenue was 58.65 billion, an increase of 22.59% compared to the previous year's 47.84 billion. Earnings were 5.28 billion, an increase of 41.22%.

Financial Statements